



Edgar Filing: Arch Therapeutics, Inc. - Form 8-K

••Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

••Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

••Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

••Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On August 15, 2016, Arch Therapeutics, Inc. (the “**Company**”) issued a press release announcing the results of the Company’s recently completed clinical trial in Western Europe using the AC5 Topical Hemostatic Device™. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibit**

(d) Exhibits

**Exhibit Description**

99.1 Press Release issued by Arch Therapeutics, Inc. on August 15, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARCH THERAPEUTICS, INC.**

Dated: August 15, 2016 By: /s/ Terrence W. Norchi, M.D.  
Name: Terrence W. Norchi, M.D.  
Title: President, Chief Executive Officer

**Exhibit List**

**Exhibit Description**

99.1 Press Release issued by Arch Therapeutics, Inc. on August 15, 2016